A bespoke rare and orphan disease medicine solution
Unlock new markets with a European network dedicated to get medicines for rare and orphan diseases to patients in Europe.
We provide an end-to-end solution for your specific needs in three steps
Step 1
Finding Patients
At Sciensus, we don’t just follow a one-size-fits-all approach.
We tailor our strategies to match the unique needs and characteristics of each disease and drug, utilizing in-country teams to engage with healthcare professionals at all levels. We collaborate with patient organizations to understand and streamline the patient experience, reducing diagnosis times.
Our efforts are further reinforced by marketing programs and peer-to-peer education, ensuring comprehensive support for better patient outcomes.
Step 2
Accessing Patients
We ensure patients get access to products safely, and on time.
With our expert regulatory understanding and knowledge of early access opportunities we can support pharma companies to provide access to product when patients need them even before commercialisation.
This combined with our efficient supply chain management allows us to work tirelessly to ensure patients get the care they need when they need it, navigating the complex healthcare landscape to make it as smooth as possible.
Step 3
Supporting Patients
We provide ongoing support and outcome monitoring for patients and their caregivers.
Our Patients Support Programs (PSP) consist of digital and/or human interventions delivered face-to-face or remotely by highly qualified Healthcare professionals (HCPs) across the whole of Europe. They enhance health outcomes and provide an opportunity to capture Patient and Clinician Reported Outcomes to generate Real-World Data .
Turn the challenges of European expansion into opportunities
Expertise
Scalability
Local access
Multilingual team
Learn more about our services from our expert team
Figures behind the facts
With over 30 years of experience collaborating with US biotech companies to offer turnkey solutions for finding and assisting patients in Europe, we are ready to go. At pace.
$ 0
orphan drugs bought and sold per year
0
relationships with healthcare providers
0
units of orphan medicine supplied
As a strategic partner, they have exceeded our expectations by finding European patients, who need our drugs, and enabling them to receive their life-extending medications.
Chief Commercial Officer at leading US Biotech company
Read the case study
Contact us
If you’d like to learn how we could help your business expand into European markets, complete the form below to get in touch.